Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Pasteur and Vivalis collaboration

Sanofi Pasteur has announced its partnership with Vivalis for the discovery and development of antibody treatments

Sanofi Pasteur, the vaccines division of sanofi-aventis (S-A), has announced its partnership with biopharmaceutical company, Vivalis, for the discovery and development of antibody treatments.

The collaboration will see Sanofi Pasteur acquire exclusive access to Vivalis' Humalex platform – a range of technologies for the discovery of fully human monoclonal antibodies targeting clinically significant infectious diseases.

Monoclonal antibodies are used in therapies to bind to specific target cells to stimulate the patient's immune system to attack the cells.

Sanofi Pasteur will also gain worldwide exclusive development and commercialisation rights for the discovered antibodies.

In return, Vivalis will receive an upfront payment of €3m, with potential milestone payments of up to €35m for each infectious disease therapy over the course of the development stage. The company will also receive royalty payments from future product sales.

"We are pleased to team up with Vivalis to discover and develop new biologicals against infectious diseases for patients worldwide," said Michel de Wilde, senior vice president, Research and Development, Sanofi Pasteur.

"Vivalis' Humalex technology allows rapid identification of clinically relevant fully human antibodies, as well as their related antigen. This opens up new medical solutions to prevent or treat serious infections."

Franck Grimaud, CEO of Vivalis, said: "This is the first major commercial agreement on the Humalex platform but it also represents a strong validation of the technology. Vivalis is today one of a very few companies able to propose a fully integrated offering from the discovery of fully human monoclonal antibodies to the production of clinical batches."

8th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Top Pharma News

TopPharmaNews.com is a global pharma magazine dedicated to delivering fresh news to society. The team at the TopPharmaNews.com cater non-biased,...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics